D.E. Shaw & Co
CDIO icon

D.E. Shaw & Co’s Cardio Diagnostics CDIO Stock Holding History

D.E. Shaw & Co’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-669
Closed -$22.3K – 4476
2022
Q4 		$22.3K Sell
669
-5,999
-90% -$648K ﹤0.01% 4512
2022
Q3 		$2.01M Hold
6,668
– – ﹤0.01% 3008
2022
Q2 		$1.99M Hold
6,668
– – ﹤0.01% 3084
2022
Q1 		$1.98M Buy
+6,668
New +$1.97M ﹤0.01% 3317

Other funds holding CDIO

LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

D.E. Shaw & Co's CDIO Position: Q1 2023 in Review

D.E. Shaw & Co sold out of Cardio Diagnostics (CDIO) in Q1 2023, closing a stake of 669 shares — an estimated $22.3K sold.

D.E. Shaw & Co first reported a position in CDIO in Q1 2022 and held it in 4 quarters. The position peaked at $2.01M in Q3 2022. 11 funds tracked by Wall St. Rank hold CDIO as of Q1 2023.

  • D.E. Shaw & Co reported no remaining Cardio Diagnostics position as of Q1 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 669 Cardio Diagnostics shares in Q1 2023, an estimated $22.3K.
  • D.E. Shaw & Co first reported a position in Cardio Diagnostics in Q1 2022 and held it in 4 quarters.
  • D.E. Shaw & Co's Cardio Diagnostics position peaked at $2.01M in Q3 2022.
  • 11 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.